Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Greenwald

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
British Journal of Haematology|December 17, 2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialJeff P Sharman, Charles M Farber, Daruka Mahadevan, et al.
Veterinary Microbiology|July 8, 2008
Animal-side serologic assay for rapid detection of Mycobacterium bovis infection in multiple species of free-ranging wildlifeK P Lyashchenko, R Greenwald, J Esfandiari, et al.
Open Forum Infectious Diseases|November 18, 2020
Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World DataMohamed N'dongo Sangaré, Jean-Guy Baril, Alexandra de Pokomandy, et al.
Blood|March 13, 2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M Barr, Gene B Saylors, Stephen E Spurgeon, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Canadian Liver Journal|August 22, 2022
Striving toward hepatitis C elimination in the era of COVID-19Charlotte Lanièce Delaunay, Zoë R Greenwald, Nanor Minoyan, et al.
Journal of Clinical Epidemiology|March 24, 2024
Validation of case-ascertainment algorithms using health administrative data to identify people who inject drugs in Ontario, CanadaZoë R Greenwald, Dan Werb, Jordan J Feld, et al.
Canadian Liver Journal|December 25, 2023
Impacts of the COVID-19 pandemic on hepatitis C elimination in Canada: Where do we go from here?Jawairia Atif, Sasha Tejna Persaud Udhesister, Mohamed N Abdelnabi, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
British Journal of Haematology|December 17, 2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialJeff P Sharman, Charles M Farber, Daruka Mahadevan, et al.
Veterinary Microbiology|July 8, 2008
Animal-side serologic assay for rapid detection of Mycobacterium bovis infection in multiple species of free-ranging wildlifeK P Lyashchenko, R Greenwald, J Esfandiari, et al.
Open Forum Infectious Diseases|November 18, 2020
Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World DataMohamed N'dongo Sangaré, Jean-Guy Baril, Alexandra de Pokomandy, et al.
Blood|March 13, 2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M Barr, Gene B Saylors, Stephen E Spurgeon, et al.
Ejhaem|July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomaLoretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Canadian Liver Journal|August 22, 2022
Striving toward hepatitis C elimination in the era of COVID-19Charlotte Lanièce Delaunay, Zoë R Greenwald, Nanor Minoyan, et al.
Journal of Clinical Epidemiology|March 24, 2024
Validation of case-ascertainment algorithms using health administrative data to identify people who inject drugs in Ontario, CanadaZoë R Greenwald, Dan Werb, Jordan J Feld, et al.
Canadian Liver Journal|December 25, 2023
Impacts of the COVID-19 pandemic on hepatitis C elimination in Canada: Where do we go from here?Jawairia Atif, Sasha Tejna Persaud Udhesister, Mohamed N Abdelnabi, et al.
Pageof 12